COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL

PURPOSE/OBJECTIVES: We set out to predict response and progression risk in recurrent high-grade glioma patients treated with hypofractionated stereotactic radiation plus pembrolizumab and bevacizumab (NCT02313272). At present RANO criteria define progression as 25% increase in sum of the products of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Glazar, Daniel, Brady, Rene, Howard, Rachel, Grass, Daniel, Arrington, John, Yu, Michael, Raghunand, Natarajan, Sahebjam, Solmaz, Enderling, Heiko
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Computational Omics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847129/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.256
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky